Co-Founder & CEO Andreas Katopodis describes the company’s three primary programs: a non-specific fusion protein that blocks the alpha receptor of IL-2 to signal CD8 cells but not T-regs, and two bispecifics that use a non-binding PD-1 as a delivery device to home on to the cancer cells.
Also look for unique social pages for BiotechTV U.
HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.
Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.
.png){kind=logo}